BlackRock Health Sciences Opportunities Portfolio (SHSCX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BlackRock Health Sciences Opportunities Portfolio (SHSCX) trades at $53.54 with AI Score 46/100 (Grade C). BlackRock Health Sciences Opportunities Portfolio (SHSCX) is a mutual fund focused on investing in equity securities of companies within the health sciences and related industries. Market cap: $5.91B, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SHSCX: SHSCX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHSCX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHSCX: the 1 perspectives are evenly split.
How is this calculated? →BlackRock Health Sciences Opportunities Portfolio (SHSCX) Financial Services Profile
BlackRock Health Sciences Opportunities Portfolio (SHSCX) is a financial services fund with a $5.91B market cap, specializing in health sciences and related industries, including healthcare equipment, biotechnology, and pharmaceuticals. The fund concentrates its investments in these sectors, potentially including non-U.S. companies, and exhibits a beta of 0.66.
What Is the Investment Thesis for SHSCX?
The BlackRock Health Sciences Opportunities Portfolio (SHSCX) presents a focused investment in the growing health sciences sector. With a market capitalization of $5.91B and a beta of 0.66, the fund offers a targeted approach to capturing potential upside in healthcare equipment, biotechnology, and pharmaceuticals. The fund's strategy of concentrating investments in health sciences allows it to capitalize on sector-specific growth drivers, such as technological advancements and increasing healthcare demand. Key value drivers include the fund's ability to identify and invest in innovative companies within the health sciences sector, as well as its potential to benefit from favorable regulatory changes and demographic trends. The absence of a dividend yield suggests a focus on capital appreciation rather than income generation. A potential risk is the fund's concentration in a single sector, which could lead to increased volatility compared to a more diversified portfolio. The fund's performance is closely tied to the overall health of the health sciences industry and its ability to navigate regulatory and competitive challenges.
Based on FMP financials and quantitative analysis
SHSCX Key Highlights
- The fund invests at least 80% of its total assets in equity securities of companies in health sciences and related industries, providing focused exposure to the sector.
- The health sciences sector includes companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals, offering diversified investment opportunities within the healthcare landscape.
- The fund concentrates its investments (i.e., invests more than 25% of its assets) in health sciences or related industries, indicating a high conviction in the sector's growth potential.
- The fund may invest in companies located in non-U.S. countries, providing global exposure to the health sciences sector.
- The fund has a market capitalization of $5.91B, reflecting its size and significance within the asset management industry.
Who Are SHSCX's Competitors?
SHSCX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FSPHX Fidelity Select Health Care Portfolio | $28.19 | +1.73% | $5.78B | 46 |
| LMGNX ClearBridge International Growth I | $77.78 | +0.04% | $7.21B | 46 |
| MUTHX Mutual Shares Corporation Cl Z (Series of Franklin Mutual Ser Fd Inc.) | $27.62 | +1.43% | $6.99B | 46 |
| PRPFX Permanent Portfolio Class I | $76.56 | +0.30% | $7.68B | 50 |
| RBAIX T. Rowe Price Balanced I Class | $29.81 | +0.40% | $5.34B | 44 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHSCX's Key Strengths?
- Strong focus on the health sciences sector.
- Managed by BlackRock, a leading global asset manager.
- Potential for high growth due to sector-specific expertise.
- Global investment reach.
What Are SHSCX's Weaknesses?
- Concentrated investment strategy increases risk.
- Performance highly dependent on the health sciences sector.
- No dividend yield may deter income-seeking investors.
- Susceptible to regulatory changes in the healthcare industry.
What Could Drive SHSCX Stock Higher?
- Increasing healthcare spending due to an aging population.
- Technological advancements in biotechnology and healthcare technology.
- Potential regulatory changes favorable to the health sciences sector.
- Expansion of healthcare services in emerging markets.
What Are the Key Risks for SHSCX?
- Economic downturn impacting healthcare spending.
- Unfavorable regulatory changes in the healthcare industry.
- Increased competition from other health sciences funds.
- Technological obsolescence in certain healthcare sub-sectors.
- Concentration risk due to focus on the health sciences sector.
What Are the Growth Opportunities for SHSCX?
- Expansion into Emerging Markets: The increasing demand for healthcare services in emerging markets presents a significant growth opportunity for SHSCX. By investing in health sciences companies that are expanding their operations in these regions, the fund can capitalize on the growing healthcare spending and increasing access to healthcare services in countries like China, India, and Brazil. The market size for healthcare in emerging markets is projected to reach $1.7 trillion by 2027, offering substantial growth potential for the fund. Timeline: Ongoing.
- Increased Investment in Biotechnology: The biotechnology industry is experiencing rapid innovation and growth, driven by advancements in genomics, personalized medicine, and gene editing. SHSCX can capitalize on this trend by increasing its investments in biotechnology companies that are developing novel therapies and diagnostic tools. The global biotechnology market is projected to reach $1.0 trillion by 2028, providing a significant growth opportunity for the fund. Timeline: Ongoing.
- Focus on Healthcare Technology: The adoption of digital health technologies, such as telehealth, remote patient monitoring, and wearable devices, is transforming the healthcare industry. SHSCX can benefit from this trend by investing in companies that are developing and commercializing these technologies. The global digital health market is projected to reach $660 billion by 2025, offering substantial growth potential for the fund. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: SHSCX can enhance its growth prospects by forming strategic partnerships with other healthcare companies or acquiring smaller, innovative companies in the health sciences sector. These partnerships and acquisitions can provide the fund with access to new technologies, markets, and expertise, enabling it to expand its investment portfolio and generate higher returns. Timeline: Ongoing.
- Capitalizing on Personalized Medicine: The rise of personalized medicine, which tailors medical treatment to individual patients based on their genetic makeup and other factors, presents a significant growth opportunity for SHSCX. By investing in companies that are developing personalized medicine technologies and therapies, the fund can capitalize on the increasing demand for more effective and targeted healthcare solutions. The global personalized medicine market is projected to reach $3.2 trillion by 2030. Timeline: Ongoing.
What Opportunities Does SHSCX Have?
- Expansion into emerging markets with growing healthcare demand.
- Increased investment in innovative biotechnology and healthcare technology companies.
- Strategic partnerships and acquisitions to enhance growth prospects.
- Capitalizing on the rise of personalized medicine.
What Threats Does SHSCX Face?
- Increased competition from other health sciences funds.
- Economic downturn impacting healthcare spending.
- Unfavorable regulatory changes in the healthcare industry.
- Technological obsolescence in certain healthcare sub-sectors.
What Are SHSCX's Competitive Advantages?
- BlackRock's brand reputation and extensive research capabilities.
- Concentrated focus on the health sciences sector.
- Global investment reach, including non-U.S. companies.
What Does SHSCX Do?
BlackRock Health Sciences Opportunities Portfolio (SHSCX) is a specialized mutual fund managed by BlackRock, Inc., a leading global investment management firm. The fund is designed to provide investors with exposure to the health sciences sector, which encompasses a wide range of industries including healthcare equipment and supplies, healthcare providers and services, biotechnology, and pharmaceuticals. The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies operating within these health-related fields. This concentration allows for a focused investment strategy targeting growth opportunities within the healthcare landscape. The fund may also invest in companies located outside of the United States, providing a global perspective on the health sciences sector. BlackRock, as the manager, brings its extensive research capabilities and investment expertise to the fund, aiming to identify companies with strong growth potential and innovative technologies. The fund's investment decisions are guided by a team of experienced portfolio managers who analyze market trends, assess company financials, and evaluate the competitive landscape within the health sciences industry. The fund's objective is to achieve long-term capital appreciation by investing in a diversified portfolio of health sciences companies. The fund's concentrated approach to the health sciences sector allows it to capitalize on the growth drivers and innovation within the industry, while also managing the inherent risks associated with investing in a specific sector. BlackRock's global presence and research capabilities provide the fund with a competitive advantage in identifying and evaluating investment opportunities in the health sciences sector worldwide.
What Products and Services Does SHSCX Offer?
- Invests primarily in equity securities of health sciences companies.
- Focuses on companies in health care equipment and supplies.
- Targets health care providers and services.
- Includes biotechnology companies in its portfolio.
- Invests in pharmaceutical companies.
- May invest in companies located in non-U.S. countries.
How Does SHSCX Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Aims to achieve long-term capital appreciation for investors.
- Concentrates investments in the health sciences sector to capitalize on industry growth.
What Industry Does SHSCX Operate In?
The asset management industry is characterized by intense competition, evolving regulatory landscapes, and increasing demand for specialized investment products. Funds like BlackRock Health Sciences Opportunities Portfolio (SHSCX) cater to investors seeking targeted exposure to specific sectors, such as health sciences. The health sciences sector is experiencing growth driven by factors such as an aging population, technological advancements, and increasing healthcare spending. SHSCX competes with other health sciences-focused funds, such as FSPHX, LMGNX, MUTHX, PRPFX, and RBAIX, as well as broader healthcare ETFs and mutual funds. The fund's success depends on its ability to identify and invest in promising companies within the health sciences sector, while also managing risks associated with sector concentration and market volatility.
Who Are SHSCX's Key Customers?
- Individual investors seeking exposure to the health sciences sector.
- Institutional investors looking for specialized investment strategies.
- Retirement savers seeking long-term growth opportunities.
How BlackRock Health Sciences Opportunities Portfolio Is Valued
Relative to its peer group, SHSCX's quantitative score of 46/100 is roughly in line with the peer average of 46/100.
SHSCX Financials
Bull Case vs Bear Case
Bull Case
- Strong focus on the health sciences sector.
- Managed by BlackRock, a leading global asset manager.
- Potential for high growth due to sector-specific expertise.
- Global investment reach.
Bear Case
- Concentrated investment strategy increases risk.
- Performance highly dependent on the health sciences sector.
- No dividend yield may deter income-seeking investors.
- Susceptible to regulatory changes in the healthcare industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SHSCX Latest News
No recent news available for SHSCX.
SHSCX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHSCX.
Price Targets
Wall Street price target analysis for SHSCX.
SHSCX MoonshotScore
What does this score mean?
The MoonshotScore rates SHSCX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
BlackRock Health Sciences Opportunities Portfolio Financial Services Stock: Key Questions Answered
What does BlackRock Health Sciences Opportunities Portfolio do?
BlackRock Health Sciences Opportunities Portfolio (SHSCX) is a mutual fund that invests primarily in the equity securities of companies operating in the health sciences and related industries. This includes companies involved in healthcare equipment and supplies, healthcare providers and services, biotechnology, and pharmaceuticals. The fund aims to achieve long-term capital appreciation by focusing its investments on companies with strong growth potential within the health sciences sector. It may also invest in companies located outside of the United States, providing a global perspective on the healthcare industry.
What are the main risks for SHSCX?
The main risks for BlackRock Health Sciences Opportunities Portfolio (SHSCX) include sector concentration risk, as the fund's performance is highly dependent on the health sciences industry. Economic downturns can impact healthcare spending, affecting the profitability of companies in the sector. Unfavorable regulatory changes, such as drug price controls or changes to healthcare reimbursement policies, can also negatively impact the fund's performance. Increased competition from other health sciences funds and technological obsolescence in certain healthcare sub-sectors pose additional risks. The fund's investments in non-U.S. companies may also be subject to currency fluctuations and political risks.
What regulatory challenges does BlackRock Health Sciences Opportunities Portfolio face?
BlackRock Health Sciences Opportunities Portfolio faces regulatory challenges inherent to both the financial services and healthcare industries. As an asset management product, it must comply with SEC regulations, including those related to fund registration, reporting, and investor protection. The fund's investments in healthcare companies are subject to healthcare-specific regulations, such as FDA approval processes for pharmaceuticals and medical devices, HIPAA privacy rules, and changes in healthcare reimbursement policies. Compliance costs can be significant, and regulatory changes can impact the profitability and growth prospects of the companies in which the fund invests.
How does BlackRock Health Sciences Opportunities Portfolio make money in financial services?
BlackRock Health Sciences Opportunities Portfolio generates revenue primarily through management fees charged on its assets under management (AUM). These fees are typically a percentage of the fund's net asset value and are used to cover the costs of managing the fund, including portfolio management, research, and administrative expenses. The fund's profitability is directly tied to its ability to attract and retain assets, as well as its investment performance. Higher AUM and strong investment returns lead to increased revenue for BlackRock, the fund's manager. The fund does not generate interest income directly, but its investments in healthcare companies may indirectly benefit from interest income earned by those companies.
What are the key factors to evaluate for SHSCX?
BlackRock Health Sciences Opportunities Portfolio (SHSCX) holds an AI score of 46/100 (low). Not financial advice.
How frequently does SHSCX data refresh on this page?
SHSCX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHSCX's recent stock price performance?
BlackRock Health Sciences Opportunities Portfolio (SHSCX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on the health sciences sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHSCX overvalued or undervalued right now?
Valuing BlackRock Health Sciences Opportunities Portfolio (SHSCX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide additional insights.
- Reliance on provided data for factual accuracy.